Educational diagram illustrating delivery systems for gene therapy and nucleic acid delivery. Panel (a) titled 'siRNA Nanoparticle Delivery Vectors' shows the mechanism of a nanoparticle vector entering a cell membrane to deliver siRNA. Below this, it categorizes five major types of delivery vectors: viruses, cationic polymers, branched dendrimers, cell-penetrating peptides, and cationic liposomes, all shown converging on a cell for 'Uptake and Biological Activity.' Panel (b) outlines the four essential characteristics of an engineered synthetic vector: 1) Biocompatibility, 2) High nucleic acid loading capacity, 3) Enhanced transfection efficiency, and 4) Desired intrinsic biological activity for additive or synergistic effects. This illustration serves as a pharmacological guide for understanding nanopharmaceutical drug delivery systems in molecular medicine and oncology.

This medical schematic illustrates a non-viral transposon-mediated gene therapy system, detailing the mechanisms of delivery, excision, and chromosomal integration. The diagram identifies two primary vector configurations: 'trans' delivery, involving two separate plasmids (one for the therapeutic gene of interest [GOI] and another for the transposase enzyme), and 'cis' delivery, where both components are housed on a single plasmid. Key molecular components include the GOI (green arrow), an upstream promoter (orange box), and flanking Inverted Terminal Repeats (ITRs, red circles). The educational focus highlights the three-step 'cut and paste' mechanism: (1) Nonviral delivery of the DNA vector into the target cell nucleus; (2) Excision of the transposon cassette by the transposase enzyme (blue) at the ITR recognition sites; and (3) Site-specific chromosomal integration into the host's genomic DNA, specifically targeting TTAA-rich sites. This process demonstrates a method for stable transgene insertion in human regenerative medicine and oncology applications, emphasizing a bi-component DNA vector system as an alternative to viral-mediated delivery.

A medical infographic illustrating common gene delivery vectors for nucleic acid therapeutics. The classification is presented as a hierarchical flowchart, branching into two primary categories: Viral vectors and Non-viral vectors. The viral vector category includes two subtypes: Lentivirus, depicted as a blue spherical particle with external glycoprotein spikes and an internal helical genetic core; and Adenovirus, shown as a yellow icosahedral capsid with protruding fibers. The non-viral vector category displays five delivery systems: Exosomes (biological vesicles with membrane-bound proteins), Inorganic nanoparticles (represented as a green textured sphere), Metal nanoparticles (depicted as a smooth yellow gold-like sphere), Lipids (shown as an orange micellar ring), and Polymers (represented as a tangled light green molecular chain). This educational diagram summarizes the diversity of vehicle designs used to deliver pDNA, mRNA, siRNA, or miRNA to target cells, such as macrophages, highlighting the morphological differences between complex biological viruses and synthetic or cellular-derived delivery platforms.

This medical infographic illustrates the mechanisms of ocular gene therapy delivery and intracellular processing. The top left features an anatomical diagram of the eye showing two primary administration routes: Intravitreal injection (into the vitreous humor) and Subretinal injection (between the retina and retinal pigment epithelium [RPE]). A cross-sectional inset details the diffusion of viral vectors through ocular barriers including the vitreous, retina, RPE, and choroid. The right and bottom panels depict a five-step cellular pathway for adenovirus-mediated delivery: 1) Diffusion through ocular barriers; 2) Evasion of immune responses, specifically non-specific phagocytosis by macrophages and degradation by nucleases; 3) Binding of the vector to target cell receptors; 4) Endosomal escape following internalization; and 5) Disassembly and cargo release within the cytoplasm. The diagram concludes by showing the fate of genetic material, where mRNA undergoes translation in the cytoplasm to produce desired proteins, while pDNA and RNP (ribonucleoprotein) complexes enter the nucleus for transcription and genome editing. This visual serves as a comprehensive educational resource for understanding ophthalmic gene therapy and molecular signaling pathways.

A pathophysiology diagram illustrating the CRISPR-Cas9 gene editing mechanism, specifically targeting anthocyanin pathways. The process begins with complex formation, where a guide RNA (gRNA)—comprised of a blue 'Scaffold' and a red 'Spacer' sequence—assembles with a yellow bean-shaped Cas9 endonuclease. The second stage demonstrates target binding, showing the Cas9-gRNA complex recognizing a double-stranded DNA target at the PAM (Protospacer Adjacent Motif) site. The next step illustrates 'Target cleavage' resulting in double-strand break (DSB) formation. The final section depicts the cellular repair mechanism 'Non-homologous end joining (NHEJ)' and its potential mutagenic outcomes: Wild Type (WT), Insertion (addition of nucleotides), Deletion (loss of DNA segments), and Frameshift mutations (disruption of the reading frame). The diagram serves as an educational summary of molecular biology techniques for precision genetic modification.

Educational diagram illustrating the CRISPR/Cas9 system and its application in herpesvirus mutagenesis. The left panel details the 'Molecular mechanism,' showing the Cas9 endonuclease guided by single-guide RNA (sgRNA) to a specific DNA target sequence upstream of a Protospacer Adjacent Motif (PAM). It depicts the creation of a double-strand break (DSB) and the two primary repair pathways: Non-homologous end joining (NHEJ), which results in random insertions/deletions, and Homology directed repair (HDR), which utilizes a repair template for precise genetic modification. The right panel outlines the workflow for 'Mutagenesis of herpesvirus.' The process begins with the transfection of a plasmid encoding Cas9 and sgRNA into host cells, followed by infection with viral particles. Within the cell, CRISPR-mediated viral DNA editing occurs. Subsequent steps include plaque purification to isolate recombinant viral clones and final sequencing and characterization to verify the mutation. This infographic is designed for intermediate to advanced molecular biology education, focusing on gene editing techniques in virology.

A medical infographic and pathophysiology diagram illustrating the application of the CRISPR/Cas9 gene-editing system in glioma research. The left side depicts the molecular mechanism: a plasmid containing sequences for sgRNA (composed of crRNA and tracrRNA) and Cas9 protein is introduced into a target cell. Within the nucleus, the sgRNA guides the Cas9 nuclease to a specific genomic target DNA site adjacent to a Protospacer Adjacent Motif (PAM), where the nuclease active domains create a double-strand break. The right side outlines six clinical and research applications of this technology in neuro-oncology: 1) Targeted knockout of tumor-related and drug-resistance genes to improve prognosis and therapy; 2) Immunotherapy, focusing on CAR T-cell and NK cell development; 3) Creation of specific animal models like mouse glioma models; 4) Mechanism research, such as tracking cell division; 5) Genetic screening for genes related to tumor infiltration; and 6) Introduction of tumor suppressor genes to inhibit tumorigenesis. The diagram effectively bridges basic molecular biology with translational oncology research for glioma.